Raised 170 million yen through a third-party allotment of new shares

iMed Technologies, Inc. (headquartered in Shibuya-ku, Tokyo; Representative Director and CEO, Kenichi Kono; hereafter “the Company”), which develops surgical support AI for endovascular surgery, has completed a third-party allotment of new shares to a fund managed by SBI Investment Co., Ltd., Globis Graduate School of Management (G-GROWTH Fund), and a fund managed by MS&AD Ventures, Inc.

Under the vision of “Delivering safe surgery to the world,” the Company is developing surgical support AI (patent pending) to improve the safety of endovascular surgery. Since its founding in April 2019, the Company has advanced its development with support from programs such as UTokyo IPC 1st Round and the NVIDIA Inception Program.

Endovascular surgery is one of the methods used to treat conditions such as ischemic stroke and subarachnoid hemorrhage. Compared with conventional open craniotomy, endovascular surgery places less burden on patients, and the number of procedures is increasing at more than 10% per year. Moreover, reports indicate that COVID-19 infection increases the risk of ischemic stroke by about sevenfold (The New England Journal of Medicine, 2020; 382:e60), suggesting that ischemic stroke may become more common in the era of living with COVID-19.

Performing endovascular surgery requires delicate maneuvers while watching multiple views simultaneously, and even small delays or misalignments can lead to complications. The brain is one of the most vital organs, and complications can result in life-threatening situations. Our CEO Kono, drawing on 16 years of clinical experience as a neurosurgeon, began developing surgical support AI using deep learning to address these clinical challenges.

With this round of financing, the Company will strengthen its R&D organization and accelerate its business to bring surgical support AI to clinical practice as soon as possible.

■iMed Technologies, Inc. Company Profile Company name: iMed Technologies, Inc. Address: 5F Eclat Shibuya, 3-6-2 Shibuya, Shibuya-ku, Tokyo Founded: April 1, 2019 Business: Development of surgical support AI for endovascular surgery Representative: Representative Director and CEO, physician Kenichi Kono

■Inquiries regarding this release Email: info@imed-tech.co.jp